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Abstract
Reservoirs of latent HIV-1 in T cells and macrophages pose one of the major obstacles that hamper final eradication of HIV-1 from
infected patients. Targeting costimulatory molecules expressed on cell types harboring latent HIV-1 to achieve reactivation may provide a
new approach to overcome this problem. One such molecule is CD40, a member of the tumor necrosis factor (TNF)-receptor family. Using
THP89GFP cells as a model for latently infected macrophages, we demonstrate that trimeric forms of recombinant CD154 allow for the
direct reactivation of latent HIV-1 infection. Reactivation is augmented by the release of TNF-. The presence of TNF- is also crucial for
the expression of late structural genes such as p24 Gag. In addition, levels of secreted TNF- are sufficiently high to reactivate latent HIV-1
in a latently HIV-1-infected T-cell line (J89GFP). Taken together, our results demonstrate that costimulatory molecules may be attractive
targets to reactivate latent HIV-1 in infected patients.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Despite its tremendous success in reducing morbidity
and mortality related to HIV-1 infection, Highly Active
Anti-Retroviral Therapy (HAART) has failed to eradicate
HIV-1 from infected patients (Palella et al., 1998). This
failure has been attributed in part to the inability of current
antiviral therapies to target reservoirs of latently infected
cells (memory T-cells and macrophages) (Chun et al., 1997,
1998, 2000; Chun and Fauci, 1999). To overcome this
problem, it is thought that therapeutically induced reactiva-
tion of HIV-1 from its latent reservoirs could make the virus
susceptible to drugs or to immune surveillance (Chun et al.,
1999). Reactivation of latent HIV-1 in vitro can be mediated
by a number of physiologic stimuli, including tumor necro-
sis factor- (TNF) , interleukin- (IL) 1, and interferon-
(IFN)  (Biswas et al., 1992; Butera et al., 1991; Folks et al.,
1987). Among them, TNF- is the most potent stimulus and
is capable of reactivating HIV-1 infection in macrophages
as well as in T-cells. Also, several chemical compounds,
such as the phorbol esters PMA (Folks et al., 1988) and
prostratin (Korin et al., 2002; Kulkosky et al., 2001) or the
deacetylase inhibitor trichostatin A (Sheridan et al., 1997;
Van Lint et al., 1996), can reactivate latent HIV-1 infection
in vitro, and their effects have been analyzed in great detail.
Less well studied is the role of costimulatory molecules
such as B7, CD28, or CD40 in HIV-1 reactivation and the
possibility to trigger HIV-1 reactivation through these mol-
ecules using recombinant proteins or antibodies.
CD40, a member of the TNF-receptor family, is a type I
transmembrane protein that is expressed on a variety of
antigen presenting cells (APCs), including macrophages
(for review see Grewal and Flavell, 1998). Its ligand
CD154, also termed CD40L, is a trimeric type II transmem-
brane protein that is transiently expressed on activated T-
cells (Casamayor-Palleja et al., 1995). Stimulation of CD40
results in direct interaction of the cytoplasmic domain of
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CD40 with TNF Receptor Associated Factors (TRAFs)
(Ishida et al., 1996; Lee et al., 1999; Pullen et al., 1999),
ultimately leading to the activation of NF-B (Lee et al.,
1999; Leo et al., 1999). Through these signaling pathways,
interaction of CD40 with its ligand CD154 leads to cellular
activation as indicated by the production of various cyto-
kines, chemokines, and increased expression of costimula-
tory molecules (Alderson et al., 1993; Caux et al., 1994).
CD40:CD154 interaction has previously been shown to
be crucial for the adaptive immune response. During viral
infection, CD154 stimulation of APCs such as macrophages
or dendritic cells induces the expression of costimulatory
molecules, including CD80 and CD86, or of adhesion mol-
ecules such as ICAM-1 (Kiener et al., 1995). By stimulating
their counterparts on T-cells (e.g., CD28 and LFA-1), these
molecules provide stimulatory signals to fully activate T-
cells following T-cell receptor stimulation (for review see
Watts and DeBenedette, 1999). For the B-cell-mediated
immune response, CD154 stimulation is of major impor-
tance, as it triggers the differentiation of activated B cells
and is a prerequisite for isotype class switching from IgM to
IgG production (Klaus et al., 1994).
In order to study the effects of CD154-mediated engage-
ment of CD40 on latent HIV-1 infection in macrophages,
we used the recently established monocytic reporter cell line
THP89GFP (Kutsch et al., 2002). Following stimulation
with various agents, these cells coordinately express infec-
tious viral particles and Enhanced Green Fluorescence Pro-
tein (EGFP). As such, EGFP can be used as a quantitative
marker for HIV-1 expression, allowing for the study of
HIV-1 reactivation at the single-cell level.
We demonstrate that addition of membrane-bound tri-
meric CD154 (mCD154), as well as soluble trimeric
CD154- (sCD154) mediated HIV-1 reactivation in
THP89GFP cells, whereas stimulation with monomeric
forms of CD154 or anti-CD40 antibodies of the IgG and
IgM type failed to do so. Despite the ability of CD154:
CD40 interaction to directly activate NF-B itself, a factor
sufficient for HIV-1 expression, HIV-1 reactivation was
augmented by CD154:CD40-mediated secretion of TNF-.
TNF- release following CD40 activation of THP89GFP
cells was essential for efficient HIV-1 late gene expression
and, in a paracrine manner, allowed for the reactivation of
latent HIV-1 in a T-cell line (J89GFP). Secretion of TNF-
was controlled by the ERK MAPK pathway and could be
blocked by the specific MEK1/2 inhibitor UO126.
These findings for the first time demonstrate the ability
of recombinant trimeric CD154 to reactivate latent HIV-1 in
a human monocytic cell line and give insights into the
mechanisms underlying CD154:CD40-mediated HIV-1 re-
activation in macrophages. A better understanding of these
mechanisms may provide future means to control persistent
reservoirs of latent HIV-1 in macrophages and T-cells,
thereby augmenting the efficiency of HAART.
Results
Reactivation of latent HIV-1 infection in THP89GFP cells
by engagement of CD40
Searching for novel strategies to reactivate latent HIV-1
infection (Butera et al., 1991; Folks et al., 1989), we inves-
tigated whether stimulation of the costimulatory molecule
CD40 with its cognate ligand CD154 would result in reac-
tivation of latent HIV-1 infection in macrophages, using the
recently established THP89GFP cells as an experimental
model (Kutsch et al., 2002). As CD154 is a trimeric trans-
membrane protein, we initially stimulated THP89GFP cells
with purified cell membranes from CD154-expressing in-
sect cells (mCD154). A single stimulation with mCD154
after 48 h resulted in reactivation of latent HIV-1 infection
in greater than 80% of the cells as indicated by EGFP
expression (Fig. 1), which is comparable to TNF- medi-
ated HIV-1 reactivation. Specificity of the effect was dem-
onstrated by preincubation of the membranes with anti-
CD154 antibody, which abrogated the effect, whereas an
isotype matched control antibody had no effect on reacti-
vation. Also, stimulation with membranes from insect cells
infected with baculovirus did not result in reactivation
(Fig. 1).
Activation of THP89GFP cells with recombinant tri-
meric soluble CD154 (sCD154) revealed similar results
(Fig. 2). Stimulation with 0.01 g/ml initiated the first
obvious reactivation of HIV-1 infection in a subset of cells
(Fig. 2A and B). sCD154 (0.1 g/ml) was sufficient to fully
reactivate HIV-1 infection on a population basis (Fig. 2A).
Higher concentrations mostly increased EGFP mean chan-
nel fluorescence (MCF), an indication of increased virus
production (Fig. 2B). sCD154 (1.0 g/ml) resulted in a level
of HIV-1 reactivation comparable to the effect achieved by
the addition of TNF- (10 ng/ml). Again, specificity of the
Fig. 1. Membrane-bound CD154 mediates HIV-1 reactivation in
THP89GFP cells. THP89GFP cells (UN) were treated for 48 h with
mCD154 (mCD154) derived from Sf9 insect cells expressing CD154 or
with control membranes (mC). To determine specificity, cells were stim-
ulated with mCD154 in the presence of neutralizing anti-CD154 antibody
(10 g/ml; mCD154/anti-CD154) or in the presence of an isotype matched
control antibody (10 g/ml; mCD154/iso). As a positive control, cells were
reactivated with TNF- (10 ng/ml). Cells were analyzed for EGFP expres-
sion by flow cytometry. Dead cells were excluded from flow cytometric
analysis by the addition of propidium iodide. The experiment is represen-
tative of three independent experiments.
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observed effect could be demonstrated by neutralization
using anti-CD154 antibody (data not shown). In contrast to
trimeric forms of CD154, stimulation with a soluble mono-
meric CD154-CD8 fusion protein did not result in reactiva-
tion of the virus (Fig. 3F).
As antibodies have proven to be suitable therapeutic
agents for a variety of pathological conditions, we also
tested whether HIV-1 reactivation could be achieved using
antibodies directed against CD40. As a baseline,
THP89GFP cells were cultured in medium (Fig. 3A) and as
Fig. 2. Soluble trimeric CD154 triggers HIV-1 reactivation in THP89GFP cells. THP89GFP cells were stimulated for 48 h with various concentrations of
soluble trimeric CD154 (0.01–1.0 g/ml) or TNF- (10 ng/ml) and HIV-1 reactivation was determined by flow cytometry. Levels of HIV-1 reactivation on
a population basis and of viral expression were quantified by determining (A) the percentage of EGFP-positive cells in the overall population and (B) the
overall EGFP MCF intensity. Dead cells were excluded from the analysis by the addition of propidium iodide. The data represent the mean  SD of five
independent experiments.
Fig. 3. Activating anti-CD40 antibodies and monomeric forms of recombinant CD154 fail to reactivate latent HIV-1 infection in THP89GFP cells.
THP89GFP cells were cultured (A) in medium or stimulated with (B) soluble trimeric CD154 (0.3 g/ml), (C) TNF- (1 ng/ml), (D) activating anti-CD40
antibody of the IgG type (clone 5C3; 1 g/ml), (E) activating anti-CD40 antibody of the IgM type (clone 14G7; 1 g/ml), and (F) soluble monomeric
CD8-CD154 fusion protein (1 g/ml). After 48 h, cells were analyzed by flow cytometry for levels of EGFP fluorescence as a marker of HIV-1 expression.
Dead cells were excluded by the addition of propidium iodide. The experiment is representative of three independent experiments.
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positive controls stimulated with either soluble trimeric
CD154 (sCD154) or TNF- (Fig. 3B and C). All antibodies
were titrated on THP89GFP cells over a wide concentration
range (0.01–10 g/ml), but stimulation of THP89GFP cells
with activating anti-CD40 antibody of the IgG type (5C3)
(Fig. 3D) or IgM type (clone 14G7; Fig. 3E) generally failed
to reactivate HIV-1 infection, even following cross-linking.
Also, stimulation with a monomeric form of recombinant
CD154 (CD8-CD154 fusion protein) did not reactivate la-
tent HIV-1 infection (Fig. 3F). These results indicate that
appropriate CD40- trimerization, as achieved by the partic-
ular nature of the receptor–ligand interaction, is likely es-
sential for virus reactivation in this system.
Influence of autocrine TNF- secretion on
CD154-mediated HIV-1 reactivation
Macrophages have been shown to secrete TNF- upon
stimulation with CD154 (Alderson et al., 1993). Since
TNF- is known to be a potent inducer of HIV-1 expression
(Butera et al., 1991), we sought to determine the possible
extent of TNF- involvement in CD154-mediated HIV-1
reactivation.
Forty-eight hours following stimulation with 1.0 g/ml
of sCD154, THP89GFP cells secreted 2.5 ng/ml TNF- as
determined by ELISA (see Fig. 7). Addition of increasing
amounts of neutralizing anti-TNF- antibody (0.1–10 g/
ml) to sCD154-stimulated THP89GFP cells decreased the
levels of HIV-1 reactivation in a concentration-dependent
manner (Fig. 4A). At 10 g/ml of anti-TNF- antibody,
EGFP MCF of the sCD154-stimulated cells was decreased
to 230 (arbitrary units; a.u.) compared to an EGFP MCF of
400 a.u. in cells that were stimulated with sCD154 and not
treated with antibody. Higher levels of anti-TNF- antibod-
ies did not further decrease sCD154-mediated HIV-1 reac-
tivation (data not shown). The occurence of reactivation
despite the presence of saturating amounts of neutralizing
anti-TNF- antibodies indicates that TNF- has a mostly
augmenting activity with respect to HIV-1 reactivation.
Following sCD154 stimulation in the presence of neu-
tralizing anti-TNF- antibody, p24 Gag expression was
decreased to a greater extent than EGFP expression (Fig.
4B), and production of infectious viral particles correlated
with p24 production (data not shown). Whereas EGFP in
THP89GFP cells is expressed as an early gene, p24 Gag is
generally considered a late gene (Malim et al., 1990). Thus,
this discrepancy between EGFP expression and p24 Gag
expression indicates that TNF- is crucial for late gene
expression in this system.
Another interesting aspect of these experiments is that
addition of neutralizing anti-TNF- antibody does not result
in a uniform decrease of HIV-1 activity in the overall
population but rather leads to a selective and complete
inhibition of reactivation in a distinct population (Fig. 4C).
The described interaction of CD154 and TNF-, essen-
tial for full HIV-1 reactivation, could be of an additive
nature or more of a kinetic kind, meaning that to achieve full
activation of the latent viral LTR, a prolonged stimulus is
required. To investigate this question, we stimulated
THP89GFP cells with an optimal concentration of sCD154
(0.3 g/ml) and added neutralizing anti-TNF- antibody
after various periods of time (0–24 h). HIV-1 reactivation
was then measured after 48 h (Fig. 5). Addition of neutral-
izing anti-TNF- antibody (10 g/ml) at the time of
Fig. 4. Contribution of autocrine secreted TNF- to sCD154-mediated reactivation of latent HIV-1 in THP89GFP cells. THP89GFP cells were stimulated
with sCD154 (1.0 g/ml) in the presence of increasing amounts of neutralizing anti-TNF- antibody (0.01–10 g/ml). After 48 h, HIV-1 reactivation was
determined by (A) measuring EGFP mean channel fluorescence (MCF) using flow cytometry or (B) determination of p24 Gag protein in the culture
supernatants by ELISA. The data represent the mean  SD of three independent experiments. (C) Flow cytometric analysis of EGFP expression in
THP89GFP cells following sCD154 stimulation in the absence or presence of neutralizing anti-TNF- antibody. Cells were treated with propidium iodide
to allow for the exclusion of dead cells.
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sCD154 stimulation and 3 or 6 h following sCD154 stim-
ulation inhibited HIV-1 reactivation to a similar level
(50%). Increased levels of reactivation could be observed
if anti-TNF- antibody was added after 12 or 24 h, but
reactivation in both cases was still inhibited when compared
to sCD154-stimulated cells that were not treated with anti-
body over the entire 48-h time period. These results dem-
onstrate that prolonged exposure to TNF- is required for
optimal reactivation and raise the possibility that CD154-
mediated CD40 stimulation, at least in THP89GFP cells,
may be of a too-transient nature to fully reactivate HIV-1
infection.
Bystander reactivation of latent HIV-1 infection in T cells
TNF- is likely the most potent physiologic activator of
HIV-1 expression in macrophages and T-cells. As T-cells
and macrophages often colocalize in certain tissues, we
investigated whether TNF- secreted by sCD154 stimulated
THP89GFP cells would also reactivate latent HIV-1 infec-
tion in T-cells. We tested this hypothesis by performing
supernatant transfer experiments using J89GFP cells, a la-
tently HIV-1 infected indicator T-cell line (Kutsch et al.,
2002) (Fig. 6). Twenty-four hours following stimulation of
THP89GFP with 0.1 and 1.0 g/ml of sCD154, THP89GFP
cells were analyzed for signs of HIV-1 reactivation (EGFP)
and cellular activation (ICAM-1). At this time point, super-
natants from the THP89GFP cultures were transferred onto
J89GFP cells. HIV-1 reactivation in J89GFP cells, 24 h
following supernatant transfer from sCD154-stimulated
THP89GFP, correlated with the levels of reactivation seen
in THP89GFP cells (Fig. 6). Reactivation was indeed trig-
gered by TNF-, and not by other factors (e.g., HIV-1 Tat),
as anti-TNF- antibodies greatly neutralized the reactivat-
ing abilities of the supernatants (90% inhition; Fig. 6).
Supernatants from sCD154-stimulated THP-1 cells, the pa-
rental cell line of THP89GFP cells, also possessed the
ability to reactivate latent HIV-1 in J89GFP cells in a
TNF--dependent manner (data not shown). This finding
demonstrates that stimulation of macrophages with sCD154
might be a promising approach to generally deplete reser-
voirs of latent HIV-1, as CD154-mediated secretion of
TNF- is also capable of reactivating latent HIV-1 in in-
fected bystander T-cells in a paracrine manner.
The role of the MAPK pathway in CD154-mediated
HIV-1 reactivation
The ERK-kinase pathway, one of the three major MAPK
pathways, has been shown to play a major role in CD40
signaling (Kashiwada et al., 1998; Suttles et al., 1999),
coupling TRAF-mediated CD40 signaling to NF-B activa-
tion (Kashiwada et al., 1998). To investigate whether the
ERK pathway is involved in sCD154-mediated HIV-1 re-
activation, THP89GFP cells were treated with various con-
centrations of the specific MEK1/2 inhibitor UO126 (0.01–
1.0 M) prior to stimulation with sCD154 (Fig. 7), and
UO126 inhibited HIV-1 reactivation by sCD154 in a con-
centration-dependent manner. Treatment with 1.0 M of
UO126, followed by stimulation with sCD154, inhibited
HIV-1 reactivation by70% as indicated by the decrease in
EGFP MCF. In parallel with the EGFP MCF, levels of
secreted TNF- decreased with increasing concentrations of
UO126 and were abrogated at 1.0 M of UO126 (sensitivity
of the TNF- ELISA: 0.01 ng/ml), suggesting that inhibi-
tion of HIV-1 reactivation by UO126 is accomplished by
abolishing TNF- secretion. Higher concentrations of
UO126 did not result in an increased inhibitory effect with
respect to HIV-1 reactivation or TNF- secretion (data not
shown). UO124, a chemically related control compound
that does not inhibit MEK-activity, had no effect on TNF-
induction and HIV-1 reactivation (data not shown). In con-
trast to the inhibitory effect of the MEK1/2 inhibitor
UO126, pretreatment of THP89GFP cells with the specific
p38 inhibitor SB202190 (1 M) did not inhibit CD40-
mediated HIV-1 reactivation (Fig. 7).
Discussion
HIV-1 latency has been connected to the reemergence of
HIV-1 after the cessation of HAART (Bukrinsky et al.,
1991; Chun et al., 1997, 1999; Chun and Fauci, 1999; Finzi
et al., 1997, 1999). Therapeutic depletion of the reservoirs
of latent HIV-1 is considered as a possibility to improve the
efficiency of HAART or even eradicate HIV-1 from the
Fig. 5. Complete CD154-induced HIV-1 reactivation requires prolonged
exposure to autocrine secreted TNF-. THP89GFP cells were stimulated
with sCD154 (0.3 g/ml) and anti-TNF- antibody (10 g/ml) was added
at various time points (0–24 h) following stimulation. The cells were
cultured for a total of 48 h and then analyzed by flow cytometry for EGFP
fluorescence to determine the level of HIV-1 reactivation, using EGFP as
a quantitative marker. The data represent the mean  SD of three inde-
pendent experiments.
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infected patients. Research thus far has largely focused on
latently infected memory T-cells, but already early on it was
demonstrated that macrophages serve as reservoirs for latent
HIV-1 (Crowe and Sonza, 2000; Lebargy et al., 1994;
Mikovits et al., 1992). The failure to target this reservoir in
the clinical attempts to reactivate HIV-1 in infected patients
may have contributed to the overall failure of these trials to
eradicate the virus. Therefore, new strategies to reactivate
HIV-1 in all potential cellular reservoirs that are well tol-
erated by the patients need to be developed. To reduce
systemic side effects, it is important to choose targets that
are unique to, or predominantly expressed on, cell types that
harbor latent HIV-1. A promising molecule in this respect is
CD40, a member of the TNF receptor family (Alderson et
al., 1993) that is expressed on macrophages, dendritic cells,
and B-cells, two of which are potential reservoirs for latent
HIV-1 (Lebargy et al., 1994; Meltzer and Gendelman, 1992;
Meltzer et al., 1990; Mikovits et al., 1992).
Using THP89GFP cells as a model for latently HIV-1-
infected macrophages (Kutsch et al., 2002), we for the first
time demonstrate that trimeric forms of recombinant CD154
possess the ability to reactivate latent HIV-1 in human cells
Fig. 6. TNF- secreted by THP89GFP cells following sCD154 stimulation potently reactivates latent HIV-1 infection in J89GFP cells. THP89GFP cells were
stimulated with sCD154 (0.1 and 1.0 g/ml) and HIV-1 reactivation 24 h following the initial sCD154 stimulation was determined by flow cytometry. At
this time point, supernatants from the THP89GFP cultures were transferred onto J89GFP cells, a latently HIV-1-infected T-cell line. Where indicated,
supernatants from THP89GFP cells stimulated with 1 g/ml of sCD154 were pretreated for 30 min with neutralizing anti-TNF- antibody (10 g/ml). After
an additional 24 h, reactivation of latent HIV-1 in J89GFP cells was measured as EGFP fluorescence using flow cytometry. The experiment is representative
of three independent experiments.
Fig. 7. Inhibition of sCD154-mediated HIV-1 reactivation in THP89GFP
cells by the MAPK inhibitor UO126. After a 2-h pretreatment with various
concentrations (0.01–1.0 M) of the specific MEK1/2 inhibitor UO126 or
with 1.0 M of the p38 inhibitor SB202190, THP89GFP cells were
stimulated with sCD154 (0.1 g/ml) and analyzed for EGFP expression
(gray bars) after 48 h. Supernatants of the respective cultures were har-
vested and analyzed for TNF- production by ELISA (black bars). The
data represent the mean  SD of three independent experiments.
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of myeloid origin. Reactivation is augmented by autocrine
secreted TNF-, which also can reactivate HIV-1 infection
in a latently infected T-cell line (J89GFP), as demonstrated
by supernatant transfer experiments. This finding raises the
possibility that in vivo, following treatment with recombi-
nant CD154, TNF- secreted by macrophages may also
reactivate latent HIV-1 in infected bystander T-cells.
Reactivation of HIV-1 infection in THP89GFP cells can
be achieved using trimeric forms of CD154, either mem-
brane bound or soluble, whereas monomeric CD154
(CD154-CD8 fusion protein) lacks the ability to reactivate
latent HIV-1. Also, different forms of anti-CD40 antibodies,
previously described as activating in other systems (Clark
and Ledbetter, 1986), fail to reactivate latent HIV-1 infec-
tion in THP89GFP cells. In a recent publication, Grassme et
al. (2002) described that clustering of CD154 is required for
clustering of its cognate receptor CD40, which in turn is key
to efficient CD40 signaling. As THP89GFP cells express
very low levels of CD40 when compared to primary cells,
treatment of the cells with antibodies may simply not result
in levels of CD40 clustering that are sufficient to trigger
HIV-1 reactivation, whereas membrane-bound CD154 and
soluble CD154, despite the low abundance of CD40, can
provide a sufficiently strong signal. Thus, whereas our re-
sults clearly demonstrate the ability of trimeric CD154
forms to reactivate HIV-1, they do not conclusively rule out
the ability of activating anti-CD40 antibodies to trigger
reactivation in primary cells.
CD154-induced HIV-1 reactivation was augmented by
autocrine secreted TNF- that was produced in response to
CD40 activation, as could be demonstrated by the addition
of neutralizing antibodies to TNF-. Most interestingly, the
depletion of TNF- from the supernatants of sCD154 stim-
ulated THP89GFP cells resulted in differential down-mod-
ulation of EGFP fluorescence and p24 Gag protein expres-
sion. As EGFP in THP89GFP is expressed as an early gene,
whereas p24 Gag is generally considered a late gene, this
finding would imply that HIV-1 late gene expression fol-
lowing CD154:CD40-mediated HIV-1 reactivation is de-
pendent on the presence of TNF-. CD154-mediated stim-
ulation of CD40, in the absence of autocrine secreted
TNF-, as expected would trigger NF-B-dependent early
gene expression, but would fail to promote late gene ex-
pression. HIV-1 late gene expression of structural genes
such as p24 Gag is dependent on Rev-mediated transport of
unspliced and singly spliced viral transcripts from the nu-
cleus to the cytoplasm (Malim et al., 1989). Although we
present no evidence at this time, it is tempting to speculate
that CD40 stimulation may result in altered expression or
activation of nuclear proteins associated with Rev function,
such as Sam68 (Reddy, 2000; Reddy et al., 1999, 2000;
Taylor and Shalloway, 1994). Sam68, the 68-kDa Src-as-
sociated protein in mitosis, has been shown to be a proto-
type regulator of alternative splicing whose function de-
pends on protein modifications in response to extracellular
cues (Matter et al., 2002). Although no data on its regulation
or activation are available for macrophages, it has been
shown that Sam68 is differentially activated by tyrosine
phosphorylation following CD2 or CD3 stimulation in T-
cells (Lang et al., 1997). Differential activation of Sam68
following CD154 and TNF- stimulation could thus explain
the observed discrepancy between EGFP and p24 Gag ex-
pression.
Although the details of this complex signal interaction
cascade clearly need more analysis, our results show that
CD40 engagement compared to TNF- stimulation is a
suboptimal trigger with respect to HIV-1 reactivation. To
cause the significant changes on the DNA and histone lev-
els, which are needed to allow full access of essential
transcription factors to the latent HIV-1 promoter (Bednarik
et al., 1987, 1990; Demarchi et al., 1993), CD40 stimulation
in the described in vitro experiments may be too transient to
result in complete reactivation in the absence of TNF-
(Lee et al., 2002). This hypothesis is emphasized by our
finding that the contribution of TNF- to CD154-mediated
HIV-1 reactivation requires prolonged exposure of
THP89GFP cells to autocrine secreted TNF-.
As we demonstrate by performing supernatant transfer
experiments, the amounts of secreted TNF- are sufficient
to mediate reactivation of latent HIV-1 in a latently infected
T-cell line in a paracrine manner. As secretion of TNF- by
macrophages following activation of CD40 has also been
described to occur under physiologic conditions, as part of
the interaction between macrophages and T-cells during
antigen presentation (for review see Grewal and Flavell,
1998), these findings suggest that targeting macrophages
may be a promising concept to deplete reservoirs of latent
HIV-1. Activation of macrophages, for example, by recom-
binant CD154, would directly reactivate latent HIV-1 in this
cell type and, through the secretion of stimulating cytokines
such as TNF-, allow for the simultaneous and indirect
depletion of reservoirs of latent HIV-1 in T-cells, which do
not express CD40.
TNF- secretion, as a part of CD154-mediated HIV-1
reactivation, is controlled by the ERK MAPK pathway. The
involvement of the mitogen-activated protein kinase
(MAPK) pathways following engagement of CD40 by its
ligand in primary monocytes and THP-1 cells has been
described previously (Pearson et al., 2001). In both cell
types, stimulation of CD40 was found to result in the tran-
sient activation of the extracellular signal-regulated kinases
1 and 2 (ERK1/2), which is consistent with our results.
Most important is the observation that addition of neu-
tralizing anti-TNF- antibody (Fig. 4) or treatment with the
ERK-inhibitor UO126 (data not shown) results not in a
uniform inhibition of HIV-1 infection but rather in a com-
plete block of reactivation in a subpopulation of the cells.
Together with the finding that TNF- at suboptimal con-
centrations only reactivates HIV-1 in a subset of
THP89GFP cells (Kutsch et al., 2002), these results indicate
that stimulation has to overcome a certain threshold to result
in reactivation. As the THP89GFP system is based on a
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transformed cell line, differences in this threshold could be
explained by differences in cell cycle at the time point of
stimulation, as suggested by previous publications (Kashan-
chi et al., 2000; Roberts et al., 1997; Tobiume et al., 1998).
On the other hand, recent publications have described that
stochastic events within a clonal population of cells can
control inducible gene expression (Elowitz et al., 2002;
Swain et al., 2002). If this were the case, attempts to reac-
tivate HIV-1 in vivo would face another challenge. Even in
resting or differentiated cells that are thought to be the
natural reservoirs of latent HIV-1 (memory T-cells and
macrophages), where cell cycle progression has no influ-
ence on the viral promoter, successful stimulation would not
necessarily result in reactivation, requiring at least pro-
longed treatment with recombinant CD154. Nevertheless, as
the control of latency on the promoter level in dividing and
thus active cells needs to be much more stringent than in
resting cells, we are convinced that the findings presented in
the THP89GFP system can be translated to differentiated
macrophages.
The ability of CD154 to reactivate HIV-1 infection is
also particularly interesting in the context of a recent pub-
lication by Cotter et al. in which they conclusively demon-
strate the ability of several factors secreted by macrophages
after CD40 stimulation, among them TNF- and MIP-1, to
inhibit HIV-1 replication by inhibiting HIV-1 transmission
and de novo infection (Cotter et al., 2001). Engagement of
CD40 would thus allow for reactivation of latent HIV-1
from its reservoirs in macrophages and T cells but simulta-
neously create an environment that is counterproductive for
de novo infection of neighboring cells.
Over the course of several years, recombinant forms of
CD154 have been successfully tested in animal models to
prevent allograft rejection and to treat various forms of
cancer (Ghamande et al., 2001; Hirano et al., 1999). In these
models, side effects were found to be limited. A recently
published Phase I study on the effects of recombinant
CD154 in cancer patients seemed to confirm these findings,
suggesting the possibility to apply short-term recombinant
CD154 therapy in patients (Vonderheide et al., 2001). In-
terest in recombinant CD154 as a means to deplete reser-
voirs of latent HIV-1 should be further sparked by a recent
publication in which Chougnet et al. demonstrate that
CD154:CD40 interaction is also involved in the activation
of HIV-1 in dendritic cells (Chougnet et al., 2001). Thus,
treatment with recombinant forms of CD154 as part of
HAART may provide a means to reactivate latent HIV-1.
Material and methods
Cell culture and reagents
THP89GFP and J89GFP cells were maintained in RPMI
1640 supplemented with 2 mM L-glutamine, 100 U/ml pen-
icillin, 100 g/ml streptomycin, and 10% heat-inactivated
fetal bovine serum, as previously described (Kutsch et al.,
2002). THP89GFP cells are semiadherent in their growth,
therefore all experiments using THP89GFP cells were per-
formed in ultralow attachment plates (Costar, Corning, NY)
to allow removal of the cells for analysis. TNF- was
obtained from R&D Systems (Minneapolis, MN). Anti-
TNF- ELISA kits and neutralizing anti-TNF- antibody
were purchased from Biosource (Camarillo, CA). PE-con-
jugated antihuman ICAM-1 antibody, as well as the acti-
vating antihuman CD40 IgG1 type antibody (clone 5C3),
were obtained from BD Pharmingen (San Diego, CA). An-
tihuman CD40 IgM-type antibodies (clone BL-C4 and
14G7) were purchased from Caltag Laboratories (Burlin-
game, CA). Soluble trimeric CD154 (sCD154) and soluble
monomeric CD154-CD8 fusion protein were purchased
from ALEXIS Biochemicals (San Diego, CA).
Production of membrane-bound CD154
mCD154 was produced by infecting Sf9 insect cells with
recombinant baculovirus containing the gene for murine
CD154 (Warren and Berton, 1995). Murine CD154 has
been demonstrated previously to cross-react with human
CD40. Control membranes were derived from mock-in-
fected Sf9 cells. Membranes were prepared by pelleting the
infected cells and exposing the pellets to three freeze–thaw
cycles. The pellets were then resuspended in PBS, trans-
ferred into a syringe, and passaged several times through a
25-gauge needle to shear the DNA. The resulting membrane
particles were pelleted at 3000 rpm and washed three times
in phosphate-buffered saline (PBS). CD154-mediated stim-
ulation of CD40 in THP-1 cells results in cell activation,
indicated by increased expression of ICAM-1. We thus
confirmed the specific activity of each mCD154 preparation
by testing the ability of neutralizing antimouse CD154 an-
tibody (R&D Systems) to inhibit mCD154-mediated stim-
ulation of ICAM-1 expression on THP-1 cells.
Supernatant transfer experiments
Supernatants from sCD154-treated THP89GFP cells
were harvested 24 h following stimulation. Following cen-
trifugation to remove residual membranes and cell debris
(10 min; 13,000 rpm), 200 l of the supernatants of each
treatment condition were transferred onto 2  105 J89GFP
cells (Kutsch et al., 2002). J89GFP cells were cultured for
24 h in 96-well flat-bottom plates and then subjected to flow
cytometric analysis for the detection of EGFP expression.
Flow cytometric analysis
Flow cytometric analysis was performed using a
FACScan or a FACStar Plus flow cytometer and CellQuest
software (Beckton–Dickinson). For analysis of EGFP ex-
pression, cells were washed with PBS and then resuspended
268 O. Kutsch et al. / Virology 314 (2003) 261–270
in PBS containing 0.01% azide and 1 g/ml propidium
iodide to allow dead cell exclusion.
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